Key Highlights

  • The loss was USD 1.47 per share, matching the estimate, against a loss of USD 2.44 a year earlier.
  • Net loss was USD 4.7 million against 7.7 million; nine month loss was USD 20.1 million against 32.5 million.
  • Research and development expense was USD 1.5 million against USD 4.3 million; general and administrative was USD 3.4 million.
  • Cash was USD 20.2 million against USD 46.3 million at year end, and the filing states Going Concern doubt.

Passage Bio, Inc. (NASDAQ:PASG) filed its Quarterly Report for the period ended September 30, 2026, on November 10, 2026. The filing shows a net loss of USD 4.7 million against USD 7.7 million a year earlier, and a loss of USD 1.47 per share, basic and diluted, against USD 2.44. The source table carried an estimate of negative USD 1.47 per share and no revenue, so the quarter matched the estimate.

Research and development expenses were USD 1,497 thousand against USD 4,307 thousand, and general and administrative expenses were USD 3,444 thousand against USD 4,348 thousand. Weighted average shares were 3,217,810 against 3,178,710.

Nine Month Results and Restructuring

For the nine months, net loss was USD 20.1 million against USD 32.5 million, and the loss per share was USD 6.26 against USD 10.26. Research and Development expenses were USD 8,933 thousand against USD 17,858 thousand, and general and administrative expenses were USD 15,104 thousand against USD 14,953 thousand.

The filing states that the company implemented a restructuring plan during the nine months that included a 75% reduction in its workforce, that it has paid USD 3.4 million in severance and related costs and that no unpaid costs remain under the plan. It also describes a January 2025 announcement to reduce its workforce by 55% and cease laboratory operations in Hopewell, New Jersey, which produced Impairment expenses in the prior year period.

Liquidity and Going Concern

Cash and cash equivalents were USD 20,160 thousand at September 30, 2026, against USD 46,303 thousand at year end. The accumulated Deficit was USD 724.9 million, and USD 15.8 million of capacity remained available under the at-the-market facility.

The filing states that the company does not anticipate its cash being sufficient to fund operating expenses and Capital Expenditure requirements for at least twelve months after the financial statements are issued, and that there is substantial doubt about its ability to continue as a going concern within one year of issuance.

Proposed Transaction and Items to Follow

The filing's forward looking statements refer to a proposed combination, a concurrent financing, a proposed reverse stock split, a Nasdaq listing for the combined company, contingent value rights for stockholders and net cash at closing. The filing is the primary source for the terms of these items. The company reported 3,217,810 shares outstanding and states it is a remote only company with no headquarters.

The filing's legal proceedings state that the company is the defendant in litigation brought by a former employee in a Philadelphia court, asserting claims for breach of contract and violation of a Pennsylvania wage statute. The filing describes the plaintiff's contentions. This item is reported neutrally here and flagged for human legal review.